Literature DB >> 28840600

Red blood cell minor antigen mismatches during chronic transfusion therapy for sickle cell anemia.

Marianne E M Yee1, Cassandra D Josephson1,2, Anne M Winkler2, Jennifer Webb3, Naomi L C Luban3, Traci Leong4, Sean R Stowell2, Ross M Fasano2.   

Abstract

BACKGROUND: Red blood cell (RBC) alloimmunization occurs at a high frequency in sickle cell anemia (SCA) despite serologic matching for Rh (C/c, E/e) and K antigens. RBC minor antigen genotyping allows for prediction of antigens and RH variants that may lead to alloimmunization. STUDY DESIGN AND METHODS: RBC antigen genotyping was performed on chronically transfused pediatric SCA patients, using PreciseType human erythrocyte antigen (HEA), RHCE, and RHD BeadChip arrays. All patients received C/c, E/e, and K serologically matched units (Category 1); patients with prior RBC antibodies were also matched for Fya , Jkb , and any antibodies (Category 2). The RBC genotypes of all leukoreduced (LR) units transfused over a 12-month period were determined by the prototype HEA-LR BeadChip assay.
RESULTS: There were 2320 RBC units transfused to 90 patients in 1135 transfusion episodes. Thirty-five (38.9%) patients had homozygous or compound heterozygous RH variants. Seven new alloantibodies were detected, with alloantibody incidence of 0.706 in 100 units for Category 2 transfusions and 0.068 in 100 units for Category 1 (p = 0.02). Three patients on Category 2 transfusions formed new anti-Jsa and had a higher rate of exposure to Jsa than those who did not form anti-Jsa (20.4 vs. 8.33 exposures/100 units, p = 0.02). The most frequent mismatches were S (43.9%), Doa (43.9%), Fya (29.2%), M (28.4%), and Jkb (28.1%).
CONCLUSIONS: Alloimmunization incidence was higher in those with prior RBC antibodies, suggesting that past immunologic responders are at higher risk for future alloimmunization and therefore may benefit from more extensive antigen matching beyond C/c, E/e, K, Fya , and Jkb .
© 2017 AABB.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28840600      PMCID: PMC5673534          DOI: 10.1111/trf.14282

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.337


  32 in total

1.  Impact of red blood cell alloimmunization on sickle cell disease mortality: a case series.

Authors:  Robert Sheppard Nickel; Jeanne E Hendrickson; Ross M Fasano; Erin K Meyer; Anne M Winkler; Marianne M Yee; Peter A Lane; Yuritzi A Jones; Farzana D Pashankar; Tamara New; Cassandra D Josephson; Sean R Stowell
Journal:  Transfusion       Date:  2015-10-28       Impact factor: 3.157

2.  Alloimmunization in sickle cell anemia and transfusion of racially unmatched blood.

Authors:  E P Vichinsky; A Earles; R A Johnson; M S Hoag; A Williams; B Lubin
Journal:  N Engl J Med       Date:  1990-06-07       Impact factor: 91.245

3.  Red blood cell alloimmunization is influenced by recipient inflammatory state at time of transfusion in patients with sickle cell disease.

Authors:  Ross M Fasano; Garrett S Booth; Megan Miles; Liping Du; Tatsuki Koyama; Emily Riehm Meier; Naomi L C Luban
Journal:  Br J Haematol       Date:  2014-09-26       Impact factor: 6.998

4.  Experience with donors matched for minor blood group antigens in patients with sickle cell anemia who are receiving chronic transfusion therapy.

Authors:  D R Ambruso; J H Githens; R Alcorn; D J Dixon; L J Brown; W M Vaughn; T Hays
Journal:  Transfusion       Date:  1987 Jan-Feb       Impact factor: 3.157

5.  Red blood cell transfusions are associated with HLA class I but not H-Y alloantibodies in children with sickle cell disease.

Authors:  Robert S Nickel; Jeanne E Hendrickson; Marianne M Yee; Robert A Bray; Howard M Gebel; Leslie S Kean; David B Miklos; John T Horan
Journal:  Br J Haematol       Date:  2015-04-19       Impact factor: 6.998

6.  Predicting the effect of transfusing only phenotype-matched RBCs to patients with sickle cell disease: theoretical and practical implications.

Authors:  Oswaldo Castro; S Gerald Sandler; Patricia Houston-Yu; Sohail Rana
Journal:  Transfusion       Date:  2002-06       Impact factor: 3.157

7.  Barriers to using molecularly typed minority red blood cell donors in support of chronically transfused adult patients with sickle cell disease.

Authors:  Matthew S Karafin; Joshua J Field; Jerome L Gottschall; Gregory A Denomme
Journal:  Transfusion       Date:  2015-03-09       Impact factor: 3.157

8.  Stochastic modeling of human RBC alloimmunization: evidence for a distinct population of immunologic responders.

Authors:  John M Higgins; Steven R Sloan
Journal:  Blood       Date:  2008-06-05       Impact factor: 22.113

Review 9.  Management of Patients with Sickle Cell Disease Using Transfusion Therapy: Guidelines and Complications.

Authors:  Stella T Chou; Ross M Fasano
Journal:  Hematol Oncol Clin North Am       Date:  2016-06       Impact factor: 3.722

10.  High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh-matched minority donors.

Authors:  Stella T Chou; Tannoa Jackson; Sunitha Vege; Kim Smith-Whitley; David F Friedman; Connie M Westhoff
Journal:  Blood       Date:  2013-05-30       Impact factor: 22.113

View more
  14 in total

1.  Antigen density dictates RBC clearance, but not antigen modulation, following incompatible RBC transfusion in mice.

Authors:  Connie M Arthur; Jerry William L Allen; Hans Verkerke; Justin Yoo; Ryan P Jajosky; Kathryn Girard-Pierce; Satheesh Chonat; Patricia Zerra; Cheryl Maier; Jen Rha; Ross Fasano; Cassandra D Josephson; John D Roback; Sean R Stowell
Journal:  Blood Adv       Date:  2021-01-26

Review 2.  Genetically-engineered pigs as sources for clinical red blood cell transfusion: What pathobiological barriers need to be overcome?

Authors:  Benjamin Smood; Hidetaka Hara; Leah J Schoel; David K C Cooper
Journal:  Blood Rev       Date:  2019-01-28       Impact factor: 8.250

3.  Initial experimental experience of triple-knockout pig red blood cells as potential sources for transfusion in alloimmunized patients with sickle cell disease.

Authors:  Takayuki Yamamoto; Mohamed H Bikhet; Marisa B Marques; Huy Q Nguyen; Yehua Cui; Mariyam Javed; Syed Sikandar Raza; David Ayares; Hayato Iwase; David K C Cooper; Hidetaka Hara
Journal:  Transfusion       Date:  2021-09-22       Impact factor: 3.157

Review 4.  Transfusion Support of Minority Patients: Extended Antigen Donor Typing and Recruitment of Minority Blood Donors.

Authors:  Jenna Khan; Meghan Delaney
Journal:  Transfus Med Hemother       Date:  2018-07-19       Impact factor: 3.747

5.  Glucose-6-phosphate-dehydrogenase deficient red blood cell units are associated with decreased posttransfusion red blood cell survival in children with sickle cell disease.

Authors:  Eyal Sagiv; Ross M Fasano; Naomi L C Luban; Cassandra D Josephson; Sean R Stowell; John D Roback; Richard O Francis; Marianne E M Yee
Journal:  Am J Hematol       Date:  2018-02-14       Impact factor: 10.047

Review 6.  Examining the Role of Complement in Predicting, Preventing, and Treating Hemolytic Transfusion Reactions.

Authors:  Connie M Arthur; Satheesh Chonat; Ross Fasano; Marianne E M Yee; Cassandra D Josephson; John D Roback; Sean R Stowell
Journal:  Transfus Med Rev       Date:  2019-10-18

7.  Towards a Regional Registry of Extended Typed Blood Donors: Molecular Typing for Blood Group, Platelet and Granulocyte Antigens.

Authors:  Jan Portegys; Gabi Rink; Pia Bloos; Erwin A Scharberg; Harald Klüter; Peter Bugert
Journal:  Transfus Med Hemother       Date:  2018-09-24       Impact factor: 3.747

8.  American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support.

Authors:  Stella T Chou; Mouaz Alsawas; Ross M Fasano; Joshua J Field; Jeanne E Hendrickson; Jo Howard; Michelle Kameka; Janet L Kwiatkowski; France Pirenne; Patricia A Shi; Sean R Stowell; Swee Lay Thein; Connie M Westhoff; Trisha E Wong; Elie A Akl
Journal:  Blood Adv       Date:  2020-01-28

9.  Hemoglobin A clearance in children with sickle cell anemia on chronic transfusion therapy.

Authors:  Marianne E M Yee; Cassandra D Josephson; Anne M Winkler; Jennifer Webb; Naomi L C Luban; Traci Leong; Sean R Stowell; John D Roback; Ross M Fasano
Journal:  Transfusion       Date:  2018-04-17       Impact factor: 3.337

10.  Marginal Zone B Cells Induce Alloantibody Formation Following RBC Transfusion.

Authors:  Seema R Patel; David R Gibb; Kathryn Girard-Pierce; Xiaoxi Zhou; Lilian Cataldi Rodrigues; Connie M Arthur; Ashley L Bennett; Ryan P Jajosky; Megan Fuller; Cheryl L Maier; Patricia E Zerra; Satheesh Chonat; Nicole H Smith; Christopher A Tormey; Jeanne E Hendrickson; Sean R Stowell
Journal:  Front Immunol       Date:  2018-11-16       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.